Conditions: Primary Myelofibrosis Post-Polycythemia Vera Post-Essential Thrombocytopenia
Keywords: Bone marrow Myelofibrosis JAK2mutation Post-Polycythemia Vera Post-Essential Thrombocytopenia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
This study assessed the safety and efficacy of Panobinostat as a single agent in the treatment of Primary Myelofibrosis, Post-Polycythemia Vera and Post-Essential Thrombocythemia. There were two cohorts - participants with JAK2 mutation and participants without JAK2 mutation.

Detailed description:

Arms:
arm 1: Participants received panobinostat 40 mg, capsules, orally, with or without food, three times a week on Monday, Wednesday, and Friday for up to 6 treatment cycles (each cycle of 28-days) with dose adjustments possible.

Interventions: intervention 1: Panobinostat
Intervention descriptions: intervention 1: Panobinostat oral capsules

Protocol document: